Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

British journal of cancer - 1 Aug 1998

Smith-Sørensen B, Kaern J, Holm R, Dørum A, Tropé C, Børresen-Dale A L

Abstract excerpt

Cell death after treatment with chemotherapy is exerted by activation of apoptosis, and the p53 protein has been shown to actively participate in this process. This recent focus on TP53 status as a possible determinant of cancer therapy response has raised the question of whether or not mutations in the TP53 gene have an influence on paclitaxel therapy. The TP53 status has been analysed at the DNA level in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cisplatin

Share to Disease-Free Survival

Share to DNA Mutational Analysis

Share to Genes, p53

Share to Mutation

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 9703286
DOI: 10.1038/bjc.1998.502
PMCID: PMC2063030

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.PMID 9703286Read ↗

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.Semantic proximity Read ↗

Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.Semantic proximity Read ↗

p53 gene status and chemosensitivity in ovarian cancer.Semantic proximity Read ↗

Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer.Semantic proximity Read ↗

Mutations of TP53 do not correlate with the sensitivity to paclitaxel--a study using 27 gynaecological cancer cell lines.Semantic proximity Read ↗

Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data.Semantic proximity Read ↗

Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications.Semantic proximity Read ↗

TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.